Biomarin Pharmaceutical Inc
A biotechnology company focused on rare genetic diseases, BioMarin makes enzyme-replacement and gene therapies—including VOXZOGO, the first drug approved to treat achondroplasia (dwarfism) in children—alongside treatments like VIMIZIM and NAGLAZYME used by patients with rare metabolic disorders. Founded in 1997 in Marin County, California, the company's name blends "bio" for biotechnology with "Marin," the county where it got its start. Its early founders deliberately took on rare diseases that bigger drugmakers ignored, and the company has since grown into one of the world's largest rare-disease biotechs.
Granted 4.70M · Bought 31.7K · Sold 3.13M
Granted 255.6K
Granted 1.22M · Bought 10.6K · Sold 936.8K
Granted 1.16M · Sold 713.6K
Granted 509.2K · Bought 9.4K · Sold 459.6K
Granted 187.0K · Bought 5.0K · Sold 43.9K
Granted 391.4K · Bought 1.5K · Sold 181.9K
Granted 296.7K · Sold 188.7K
Granted 199.6K · Sold 40.4K
Granted 1.08M · Bought 6.0K · Sold 801.9K
Granted 497.1K · Sold 296.4K
Granted 504.2K · Bought 3.1K · Sold 466.2K
Granted 320.2K · Bought 11.3K · Sold 277.9K
Granted 66.4K · Sold 9.6K
Granted 37.0K · Bought 12.8K
Granted 49.4K
Granted 165.3K · Sold 92.5K
Granted 428.5K · Sold 270.3K
Granted 50.9K · Sold 4.4K
Granted 48.5K · Sold 273
Granted 41.9K
Granted 46.5K · Sold 6.4K
Granted 35.5K
Granted 67.5K · Bought 20.0K · Sold 62.0K
Granted 156.4K · Sold 124.7K
Granted 123.8K · Bought 9.0K · Sold 100.0K
Granted 25.6K
Granted 173.2K · Sold 139.2K
Granted 21.0K
Granted 21.0K
Granted 21.0K
Granted 293.6K · Bought 588 · Sold 268.3K
Granted 4.7K
Granted 17.3K
Granted 11.5K · Bought 3.6K
Granted 15.0K · Sold 37.5K
Granted 14.5K
Granted 25.6K · Sold 7.4K
Granted 127.0K · Sold 125.0K
Granted 11.9K
Granted 11.9K
Granted 2.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bienaime Jean JacquesDirector · 995 transactions | — | 721.3Kas of May 2024 | 4.70M | 31.7K | 3.13M |
| Hardy AlexanderChief Executive Officer, Director · 12 transactions | — | 214.6K | 255.6K | — | — |
| Baffi RobertPresident, Global Mfg/Tech Ops · 620 transactions | — | 189.0Kas of Mar 2020 | 1.22M | 10.6K | 936.8K |
| Fuchs Henry JPresident, Worldwide R&D · 238 transactions | — | 185.1Kas of Sep 2024 | 1.16M | — | 713.6K |
| Aselage SteveEVP, Chief Business Officer · 122 transactions | — | 154.4Kas of Jul 2012 | 509.2K | 9.4K | 459.6K |
| Meier Richard ADirector · 55 transactions | — | 126.9K | 187.0K | 5.0K | 43.9K |
| Mueller BrianEVP, Chief Financial Officer · 187 transactions | — | 123.3K | 391.4K | 1.5K | 181.9K |
| Heron Elaine JDirector · 110 transactions | — | 101.9Kas of Jun 2024 | 296.7K | — | 188.7K |
| Guyer Charles GregEVP, Chief Technical Officer · 43 transactions | — | 84.1K | 199.6K | — | 40.4K |
| Davis George EricEVP, Chief Legal Officer · 306 transactions | — | 78.6K | 1.08M | 6.0K | 801.9K |
| Ajer Jeffrey RobertEVP, Chief Commercial Officer · 184 transactions | — | 66.8Kas of May 2024 | 497.1K | — | 296.4K |
| Cooper Jeffrey HSVP, Chief Financial Officer · 138 transactions | — | 66.3Kas of May 2012 | 504.2K | 3.1K | 466.2K |
| Kakkis Emil DChief Medical Officer · 185 transactions | — | 56.8Kas of Mar 2009 | 320.2K | 11.3K | 277.9K |
| Friberg Gregory REVP, Chief R&D Officer · 9 transactions | — | 51.8K | 66.4K | — | 9.6K |
| Pyott David E IDirector · 12 transactions | — | 49.8Kas of May 2024 | 37.0K | 12.8K | — |
| Hombach Robert J.Director · 10 transactions | — | 49.4K | 49.4K | — | — |
| Grey Michael GDirector · 67 transactions | — | 47.8Kas of Mar 2021 | 165.3K | — | 92.5K |
| Spiegelman Daniel KEVP, Chief Financial Officer · 108 transactions | — | 47.7Kas of Apr 2019 | 428.5K | — | 270.3K |
| Dere Willard HDirector · 12 transactions | — | 46.4K | 50.9K | — | 4.4K |
| Hubbard CristinEVP, Chief Commercial Officer · 10 transactions | — | 42.5K | 48.5K | — | 273 |
| Anderson Elizabeth MDirector · 8 transactions | — | 41.9K | 41.9K | — | — |
| Slamon DennisDirector · 19 transactions | — | 40.8Kas of Mar 2024 | 46.5K | — | 6.4K |
| Ho MaykinDirector · 7 transactions | — | 35.5K | 35.5K | — | — |
| Klein Joseph IIIDirector · 24 transactions | — | 35.0Kas of Mar 2010 | 67.5K | 20.0K | 62.0K |
| Lawlis V BryanDirector · 68 transactions | — | 33.1Kas of May 2023 | 156.4K | — | 124.7K |
| Lapalme PierreDirector · 66 transactions | — | 32.8Kas of Jun 2015 | 123.8K | 9.0K | 100.0K |
| Ramchandani Rashmi VirendraVP, Chief Accounting Officer · 2 transactions | — | 25.6K | 25.6K | — | — |
| Lewis AlanDirector · 51 transactions | — | 25.6Kas of Jun 2019 | 173.2K | — | 139.2K |
| Bodem Barbara W.Director · 4 transactions | — | 21.0K | 21.0K | — | — |
| Countouriotis AthenaDirector · 4 transactions | — | 21.0K | 21.0K | — | — |
| Enyedy Mark JDirector · 4 transactions | — | 21.0K | 21.0K | — | — |
| Wood MarkVP, Human Resources · 462 transactions | — | 20.3Kas of May 2013 | 293.6K | 588 | 268.3K |
| Acosta AndreaGVP, Chief Accounting Officer · 7 transactions | — | 18.1Kas of Jul 2021 | 4.7K | — | — |
| Walbert Timothy PDirector · 3 transactions | — | 17.7K | 17.3K | — | — |
| Alles Mark JDirector · 4 transactions | — | 15.1Kas of May 2023 | 11.5K | 3.6K | — |
| Sager ErichDirector · 7 transactions | — | 14.8Kas of Feb 2006 | 15.0K | — | 37.5K |
| Clark Ian TDirector · 2 transactions | — | 14.5K | 14.5K | — | — |
| Burkhart ErinGVP, Chief Accounting Officer · 14 transactions | — | 14.2Kas of May 2025 | 25.6K | — | 7.4K |
| Swiedler Stuart JSVP, Clinical Affairs · 111 transactions | — | 12.0Kas of Jul 2008 | 127.0K | — | 125.0K |
| Bate KennethDirector · 5 transactions | — | 11.9Kas of Jun 2015 | 11.9K | — | — |
| Young William DDirector · 5 transactions | — | 11.9Kas of Jun 2015 | 11.9K | — | — |
| Falberg Kathryn EDirector · 1 transaction | — | 2.6Kas of Jul 2016 | 2.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -8.66M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.